


REMARKS

The only issue outstanding in the Office Action mailed July 16, 2002, is the rejection of all claims under the doctrine of obviousness-type double patenting over USP 6,187,799. Reconsideration of this rejection, in view of the following discussion, is respectfully requested.

It is argued, at page 2 of the Office Action, that although the conflicting claims are not identical, they are not patentably distinct because a substantial amount of the compounds in the claims are identical. However, it is important to note that not all of the compounds, in fact, are identical. It is submitted that there is simply no motivation for one of ordinary skill in the art to make the full scope of the present claims, in view of the claims of the cited patent. Withdrawal of the rejection is again respectfully requested.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

 (33,103)

Harry B. Shubin Reg. No. 32,004
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

FILED: January 16, 2003

K:\Bayer\1 D1\REPLY.doc